___

• 1. Emre M. Voltaj kapılı kalsiyum kanalları ve moleküller özellikleri. Arşiv Kaynak Tarama Dergisi 2018;27(1):1–17. 2. Ibrahim HS, Maryam IU, Nasir Mohamad, Mahadeva R, Adzim K, Nor Hidayah AB. Reviews on calcium mediated secondary messengers in chronic opioids exposure/addiction. Journal of Applied Pharmaceutical Science 2015;5(01), 114–119. 3. William AC, Edward PR, Terrance PS, Joerg S. International union of pharmacology. XLVIII. Nomenclature and structurefunction relationships of voltage-gated calcium channels. Pharmacol Rev 2005;57(4):411–25. 4. Thomas L. Pallone, Sandeep Khurana, Chunhua Cao. Voltage-Gated Calcium Channels: Structure and Function (CACNA)2017;5942–49. 5. Simms BA, Zamponi GW. Neuronal Voltage-Gated Calcium Channels: Structure, Function, and Dysfunction. Neuron 2014;82(1):24–45. 6. Sümer Turanlıgil NC, Uyanıkgil Y. Hücre İçi Sinyal Yolakları ve Klinik Yansımaları. Arşiv 2010;19:180–191. 7. Zhang Z, Xu Y, Song H, Rodriguez J, Tuteja D, Namkung Y, et al. Functional roles of Ca (v)1 3(alpha(1D))calcium channel in sinoatrial nodes: insight gained using gene-targeted null mutant mice. Circ Res 2002;90:981–87. 8. Triggle DJ. L-type calcium channels. Curr Pharm Des 2006;12(4):443–57. 9. Safa P, Boulter J, and Hales TG. Functional properties of Cav1 3(alpha1D) L-type Ca2+ channel splice variants expressed by rat brain and neuroendocrine GH3 cells. J Biol Chem 2001;276:38727–37. 10. Xu W and Lipscombe D. Neuronal Ca (V)1 3alpha(1)L-type channels activate at relatively hyperpolarized membrane potentials and are incompletely inhibited by dihydropyridines. J Neurosci 2001;21:5944–51. 11. Thomas DH, Weifeng Xu, and Diane Lipscombe. Neuronal L-type calcium channels open quickly and are inhibited slowly. The Journal of Neuroscience 2005;25(44):10247–51. 12. Platzer J, Engel J, Schrott-Fischer A, Stephan K, Bova S, Chen H, et al. Congenital deafness and sinoatrial node dysfunction in mice lacking class D L-type Ca2+ channels. Cell 2000;102:89–97. 13. Valentin KG. The role of voltage-gated calcium channels in pain and nociception. Seminars in Cell & Developmental Biology 2006;17:555–64. 14. Gruner W, Silva LR. Omega-conotoxin sensitivity and presynaptic inhibition of glutamatergic sensory neurotransmission in vitro. J Neurosci1994;14:2800–2808. 15. Mills LR, Niesen CE, So AP, Carlen PL, Spigelman I, Jones OT. N-type Ca2+ channels are located on somata, dendrites, and a subpopulation of dendritic spines on live hippocampal pyramidal neurons. J Neurosci 1994;14(11):6815–24. 16. Jason E Pope, Timothy R. Deer. Ziconotide: a clinical update and pharmacologic review. Journal Expert Opinion on Pharmacotherapy 2013;14(7):957–966. 17. Emilie P, Michel V, Jean M, Valerie R. Peptide Neurotoxins That Affect Voltage-Gated Calcium Channels: A Close-Up on ω-Agatoxins. Toxins 2011, 3(1), 17–42. 18. Wallace MS, Kosek PS, Staats P, Fisher R, Schultz DM, Leong M. Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain. Pain Med 2008;9(3):271–81. 19. Staats PS, Yearwood T, Charapata SG, Presley RW, Wallace MS, Byas-Smith M, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS. J Am Med Assoc 2004;291(1):64–70. 20. Dray A, Read SJ. Arthritis and pain. Future targets to control osteoarthritis pain. Arthritis Research & Therapy 2007;9(212):1–14. 21. Javed S, Petropoulos IN, Alam U, Malik RA. Treatment of painful diabetic neuropathy. Therapeutic Advances in Chronic Disease 2015;6(1):15–28. 22. Bruel BM, Burton AW. Intrathecal Therapy for Cancer-Related Pain. Pain Medicine 2016;17(12):2404–21. 23. Webster LR, Fakata KL, Charapata S, Robert F, Michael MH. Open-label, multicenter study of combined intrathecal morphine and ziconotide: Addition of morphine in patients receiving ziconotide for severe chronic pain. Pain Med 2008;9:282–90. 24. Dupoiron D, Bore F, Lefebvre-Kuntz D, Brenet O, Debourmont S, Dixmerias F, et al. Ziconotide Adverse Events in Patients with Cancer Pain: A Multicenter Observational Study of a Slow Titration, Multidrug Protocol. Pain Physician 2012;15:395–403. 25. McGuire D, Bowersox S, Fellmann JD, Luther RR. Sympatholysis after neuron-specific, N-type, voltagesensitive calcium channel blockade: first demonstration of N-channel function in humans. J Cardiovasc Pharmaco 1997;30:400–403. 26. Kolosov A, Aurini L, Williams ED, Cooke I, Goodchild CS. Intravenous injection of leconotide, an omega conotoxin: synergistic antihyperalgesic effects with morphine in a rat model of bone cancer pain. Pain Medicine 2011;12(6), 923–941. 27. Williams ME, Brust PF, Feldman DH, Patthi S, Simerson S, Maroufi A, et al. Structure and functional expression of an omega-conotoxin-sensitive human N-type calcium channel. Science 1992;257:389–395. 28. Weber AM, Wong FK, Tufford AR, Schlichter LC, Matveev V, Stanley EF. N-type Ca2+ channels carry the largest current: implications for nanodomains and transmitter release. Nature Neuroscience 2010;13(11):1348–50. 29. Valentin KG and Leonard KK (Eds). Structure, Function, and Modulation of Neuronal Voltage-Gated Ion Channels. Elizabeth T and Terrance PS. Voltage-gated N-type and T-type calcium channels and excitability disorders 2009;35–66, John Wiley & Sons, Inc. doi:10 1002/9780470429907. ch2. 30. Alles SRA, Smith PA. Etiology and Pharmacology of Neuropathic Pain. Pharmacol Rev 2018;70(2):315–347. 31. Li CY, Song YH, Higuera ES, Luo ZD. Spinal dorsal horn calcium channel α2 δ-1 subunit upregulation contributes to peripheral nevre injury-induced tactile allodynia. J Neurosci 2004;29(39):8494–99. 32. Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2 delta subunit of a calcium channel. J Biol Chem 1996;271:5768–76. 33. Kavoussi R. Pregabalin: From molecule to medicine. Eur Neuropsychopharmacol 2006;16:28–33. 34. Shneker BF, McAuley JW. Pregabalin: a new neuromodulator with broad therapeutic indications. Ann Pharmacother 2005;39(12):2029–37. 35. Dworkin RH, O’Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, at al. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain 2007;132:237–251. 36. Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP Jr, Martin SA, et al. A randomized, double-blind, placebocontrolled, phase III trial of Pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008;35:502–14. 37. Olivera BM, McIntosh JM, Cruz LJ, Luque FA, Gray WR. Purification and sequence of a presynaptic peptide toxin from Conus geographus venom. Biochemistry 1984;23:5087–90. 38. Ryan M. Brady, Jonathan B. Baell and Raymond S. Norton. Strategies for the development of conotoxins as new therapeutic leads. Mar. Drugs 2013;11:2293–2313. 39. Olivera BM, Cruz LJ, de Santos V, LeCheminant GW, Griffin D, Zeikus R, et al. Neuronal calcium channel antagonists Discrimination between calcium channel subtypes using omega-conotoxin from Conus magus venom. Biochemistry 1987;26:2086–90. 40. Wang YX, Pettus M, Gao D, Phillips C, Scott Bowersox S. Effects of intrathecal administration of ziconotide, a selective neuronal N-type calcium channel blocker, on mechanical allodynia and heat hyperalgesia in a rat model of postoperative pain. Pain 2000;84:151–8. 41. Staats PS, Yearwood T, Charapata SG, Presley RW, Wallace MS, Byas-Smith M, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS. a randomized controlled trial. JAMA 2004;291:63–70. 42. Ver Donck A, Collins R, Rauck RL, Nitescu P. An open-label, multicenter study of the safety and efficacy of intrathecal ziconotide for severe chronic pain when delivered via an external pump. Neuromodulation 2008;11:103–11. 43. Richard JL, Se´bastien Dutertre, Irina Vetter, and MacDonald J. Conus Venom Peptide Pharmacology. Pharmacological Reviews 2012;64(2):259–298. 44. Peter D. Anderson, Gyula Bokor. Conotoxins: Potential Weapons from the Sea. J Bioterr Biodef 2012;3(3), 1–4. 45. Thomas D. Helton, Weifeng Xu, and Diane Lipscombe. Neuronal L-type calcium channels open quickly and are inhibited slowly. The Journal of Neuroscience 2005;25(44):10247–51. 46. Martinello K, Huang Z, Lujan R, Tran B, Watanabe M, et al. Cholinergic afferent stimulation induces axonal function plasticity in adult hippocampal granule cells. Neuron 2015;85:346–63. 47. Perez-Reyes E. Molecular physiology of low-voltage-activated t-type calcium channels. Physiol Rev 2003;83:117–161. 48. McRory JE, Santi CM, Hamming KS, Mezeyova J, Sutton KG, Baillie DL, et al. Molecular and functional characterization of a family of rat brain T-type calcium channels. J Biol Chem 2001;276:3999–4011. 49. Heron SE, Phillips HA, Mulley JC, Mazarib A, Neufeld MY, Berkovic SF, et al. Genetic variation of CACNA1H in idiopathic generalized epilepsy. Ann Neurol 2004;55:595–596. 50. Yue J, Liu L, Liu Z, Shu B, Zhang Y. Upregulation of T-type Ca2+ channels in primary sensory neurons in spinal nerve injury. Spine 2013;38:463–70. 51. Messinger RB, Naik AK, Jagodic MM, Nelson MT, Lee WY, Choe WJ, et al. In vivo silencing of the Cav3 2 T-type calcium channels in sensory neurons alleviates hyperalgesia in rats with streptozocininduced diabetic neuropathy. Pain 2009;145:184–195. 52. Wen XJ, Xu SY, Chen ZX, Yang CX, Liang H, Li H. The roles of T-type calcium channel in the development of neuropathic pain following chronic compression of rat dorsal root ganglia. Pharmacology 2010;85:295–300. 53. Chen WK, Liu IY, Chang YT, Chen YC, Chen CC, Yen CT, et al, Ca (v)3 2 T-type Ca2+ channel-dependent activation of ERK in paraventricular thalamus modulates acid-induced chronic muscle pain. J Neurosci 2010;30:10360–68. 54. Engbers JD, Anderson D, Asmara H, Rehak R, Mehaffey WH, Hameed S, et al. Intermediate conductance calcium-activated potassium channels modulate summation of parallel fiber input in cerebellar Purkinje cells. Proc Natl Acad Sci USA 2012;109:2601–06. 55. E. Bourinet, A Francois, S Laffray. T-type calcium channels in neuropathic pain. Pain 2016;157 S15-S22. 56. Barton ME, Eberle EL, Shannon HE. The antihyperalgesic effects of the T-type calcium channel blockers ethosuximide, trimethadione, and mibefradil. Eur J Pharmacol 2005;521:79–85. 57. Jagodic MM, Pathirathna S, Joksovic PM, Lee W, Nelson MT, Naik AK, et al. Up-regulation of the T-type calcium current in small rat sensory neurons after chronic constrictive injury of the sciatic nerve. J Neurophysiol 2008;99:3151–56. 58. Michael E. Hildebrand, Terrance P. Snutch. Contributions of T-type calcium channels to the pathophysiology of pain signaling. Pain 2006:3(3):335–341. 59. Haitao Y, Vinicius MG, Ravil RP, Gerald WZ, Philippe D. Functional characterization and analgesic effects of mixed cannabinoid receptor/T-type channel ligands. Molecular Pain 2011;7(89):1–12. 60. Huc S, Monteil A, Bidaud I, Barbara G, Chemin J, Lory P. Regulation of T-type calcium channels: signalling pathways and functional implications. Biochim Biophys Acta 2009;1793:947–952. 61. Chemin J, Monteil A, Perez-Reyes E, Nargeot J, Lory P. Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. EMBO J 2001;20:7033–40. 62. Park JY, Remy S, Varela J, Cooper DC, Chung S, Kang HW, et al. A post-burst after depolarization is mediated by group I metabotropic glutamate receptor- dependent upregulation of Ca (v)2 3 R-type calcium channels in CA1 pyramidal neurons. PLoS Biol 2010;8(11):1–17. 63. Naidoo V, Dai X, Galligan JJ. R-type Ca2+ channels contribute to fast synaptic excitation and action potentials in subsets of myenteric neurons in the guinea pig intestine. Neurogastroenterol Motil 2010;22: e353–363. 64. Pietrobon D, Moskowitz MA. Pathophysiology of migraine. Annu Rev Physiol 2013;75:365–391. 65. Nebe J, Vanegas H, Neugebauer V, Schaible HG. Omegaagatoxin IVA, a P-type calcium channel antagonist, reduces nociceptive processing in spinal cord neurons with input from the inflamed but not from the normal knee joint-an electrophysiological study in the rat in vivo. Eur J Neurosci 1997;9:2193–2201. 66. Charles P Taylor. Mechanisms of analgesia by gabapentin and pregabalin Calcium channel α2-δ (Cavα2-δ) ligands. Pain 2009;142(1–2):13–6. 67. Ebersberger A, Portz S, Meissner W, Schaible HG, Richter F. Effects of N-, P/Q- and L-type calcium channel blockers on nociceptive neurones of the trigeminal nucleus with input from the dura. Cephalalgia 2004 Apr; 24(4):250–61. 68. Gurkoff G, Shahlaie K, Lyeth B, Berman R. Calcium Channel Antagonists and traumatic Brain Injury. Pharmaceuticals 2013, 6(7), 788–812.